Allison Shelbourn
YOU?
Author Swipe
View article: BIOM-06. HOXD12 EXPRESSION PATTERNS ACROSS PRIMARY AND METASTATIC BRAIN TUMORS
BIOM-06. HOXD12 EXPRESSION PATTERNS ACROSS PRIMARY AND METASTATIC BRAIN TUMORS Open
Dysregulation of developmentally regulated HOX genes has been implicated in various cancers, including primary central nervous system (CNS) tumors. Our previous work identified a significant subset of oligodendrogliomas, IDH-mutant and 1p/…
View article: HOXD12 defines an age-related aggressive subtype of oligodendroglioma
HOXD12 defines an age-related aggressive subtype of oligodendroglioma Open
View article: Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype Open
Glioblastoma is universally fatal and characterized by frequent chromosomal copy number alterations harboring oncogenes and tumor suppressors. In this study, we analyzed exome-wide human glioblastoma copy number data and found that cytoban…
View article: Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes
Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes Open
View article: MODL-41. LOSS OF DISTAL CHROMOSOME 6Q AND ASSOCIATED <i>PDE10A</i> INDUCES AN AGGRESSIVE GLIOMA PHENOTYPE BY FACILITATING PRONEURAL TO MESENCHYMAL TRANSITION
MODL-41. LOSS OF DISTAL CHROMOSOME 6Q AND ASSOCIATED <i>PDE10A</i> INDUCES AN AGGRESSIVE GLIOMA PHENOTYPE BY FACILITATING PRONEURAL TO MESENCHYMAL TRANSITION Open
Somatic copy number alterations (SCNAs) are common in glioblastoma, with some SCNAs having prognostic implications. Identifying and characterizing SCNA-related genes acting as oncogenes or tumor suppressors may potentially provide new ther…
View article: BIOM-54. VALIDATING MCM2 IMMUNOHISTOCHEMISTRY AS A SURROGATE MARKER FOR AGGRESSIVE MENINGIOMA
BIOM-54. VALIDATING MCM2 IMMUNOHISTOCHEMISTRY AS A SURROGATE MARKER FOR AGGRESSIVE MENINGIOMA Open
Increasing efforts have focused to improve meningioma classification through various multi-omic analyses. One such recent study (Nassiri, et al, Nature, 2021) proposed an integrative molecular classification for meningiomas that included 4…
View article: Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype
Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype Open
View article: EXTH-76. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA NEUROSPHERES TO TEMOZOLOMIDE
EXTH-76. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA NEUROSPHERES TO TEMOZOLOMIDE Open
INTRODUCTION The median survival of Glioblastoma (GBM) patients is less than two years with the standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) chemotherapy. Protein Arginine Methyltransferase 5 (PRMT5), w…